First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Johnson & Johnson

    JNJ · 71 developments mapped · last assessed 2026-09-26

    Market Ontology has mapped 71 macro, policy, and market developments to Johnson & Johnson since 2026-08-11. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for JNJ yet, so no modelled value is shown. The JNJ valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run JNJ on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for JNJ. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      Citadel increases AbbVie stake over 500% amid institutional yield rotation

      Second-order effect: Similar characteristics (large-cap, healthcare, dividend payer) make it a likely beneficiary of the same institutional yield rotation.

      · Moves cost of equity (ke) due to lower perceived risk and higher demand, market multiple expansion

    • Main threat

      10-Year Treasury yield approaches 5.0%, compressing defensive dividend risk premiums

      Increased competition for passive income from risk-free assets; higher discount rates reduce present value of future dividends.

      · Moves equity risk premium, cost of capital

    • Open question

      Over 40 Late-Stage Hypertension Trials Progress Across RNAi and Novel Pathways

      Similar to Pfizer, J&J has a broad pharmaceutical presence and could benefit from new opportunities but also face increased competition.

      · Moves probability of success pipeline, addressable market size, competitive landscape

    What changed, by assumption

    Equity risk premium
    • 2026-09-1810-Year Treasury yield approaches 5.0%, compressing defensive dividend risk premiums
    Cost of equity (ke) due to lower perceived risk and higher demand
    • 2026-09-15Citadel increases AbbVie stake over 500% amid institutional yield rotation
    Cost of equity decreases due to lower perceived risk and higher demand
    • 2026-09-15Citadel Expands AbbVie Position Over 500% in Q2 Amid Defensive Rotation
    Cost of equity (lower due to perceived lower risk)
    • 2026-09-15Citadel Expands AbbVie Stake Over 500% as High Yields Drive Defensive Rotation
    Sales forecasts for competing long acting injectables
    • 2026-09-19Teva Clinical Evidence Highlights UZEDY Treatment Retention and Cost Reductions

    Assumption changes

    Full ledger →
    DateAssumptionDirectionWhyConf.
    2026-09-12Valuation multipleBullishTarget re-rates to bid premium until close.0.70
    2026-07-15RevenueBullishCompany raised 2026 guidance to $101.1 Billion midpoint based on strong operational performance.1.00
    2026-07-15RevenueBullishCompany raised 2026 sales guidance to $101.1 Billion at the midpoint.1.00
    2026-07-15RevenueBullishCompany raised 2026 guidance with estimated reported sales of $101.1 Billion.1.00
    2026-07-15Share countBullishStock component of consideration dilutes existing acquirer holders.0.70
    2026-07-15Net debtBullishCash component of consideration is typically debt-funded, raising net debt.0.70
    2026-07-15RevenueBullishAcquisition adds target revenue to acquirer P&L on close.0.70
    2026-07-15MarginBullishCompany increased adjusted EPS guidance by $0.13 to $11.68.0.95
    2026-07-15RevenueBullishCompany raised 2026 guidance to estimated reported sales of $101.1 Billion.1.00

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-26C4 Therapeutics Presents Cemsidomide Multiple Myeloma Phase 1 Biomarker Datawatch3-12m0.20
    2026-09-26C4 Therapeutics presents cemsidomide Phase 1 biomarker data at IMSwatch3-12m0.20
    2026-09-24Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorderwatch3-12m0.10
    2026-09-24Kyverna Therapeutics Reports Positive One-Year Data for Miv-cel; Rolling BLA Submission on Track for Q4 2026watch3-12m0.20
    2026-09-24HUTCHMED and AstraZeneca Present Phase III Lung Cancer Data at ESMOBearish3-12m0.30
    2026-09-21Alkermes Announces Positive Phase 1b Results for ALKS 7290 in Adults With ADHDwatch1-5y0.20
    2026-09-21Bristol Myers Squibb Posts $12.9B Revenue as New Therapies Reach 60% of Mixmixed3-12m0.10
    2026-09-21Bristol Myers Squibb growth portfolio reaches 60% of revenue with 153% Q2 EPS growthmixed1-3m0.30
    2026-09-21Bristol Myers Squibb Posts $12.9B Revenue as Growth Portfolio Hits 60%watch3-12m0.20
    2026-09-21Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue in Q2mixed3-12m0.40
    2026-09-19Teva Highlights Real-World Data Demonstrating UZEDY Superiority in Treatment ContinuityBearish1-3m0.40
    2026-09-19Teva presents real-world data showing UZEDY treatment continuity advantagewatch3-12m0.20